Publications

ADG126

Deciphering Improved Clinical Therapeutic Index (TI) of Muzastotug (ADG126), a Masked Anti-CTLA-4 SAFEbody^® over its Unmasked Form (ADG116) as Monotherapy or in Combination with anti-PD-1 Therapy (Toripalimab)
ADG126 | SITC 2024

Phase 1b/2, Multicenter Dose Escalation and Expansion Study of Muzastotug (ADG126, a Masked Anti-CTLA-4 SAFEbody^®) in Combination with Pembrolizumab in Advanced/Metastatic MSS CRC
ADG126 | SITC 2024

Increased Therapeutic Index of Muzastotug (ADG126), a Masked Anti-CTLA-4 Antibody, in Combination with Pembrolizumab (Pembro) Enables Significant Clinical Benefits and Supports Further Clinical Development in Patients with Metastatic MSS CRC
ADG126 | ESMO 2024

Results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody) in combo with pembrolizumab (Pembro) in patients (Pts) with metastatic microsatellite-stable (MSS) colorectal cancer (CRC)
ADG126 | ASCO-GI 2024

Optimal Dose Selection of ADG126 (Masked Anti-CTLA-4 SAFEbody^®) with Significantly Widened Therapeutic Index Compared to Ipilimumab in Combination with anti-PD-1 Antibodies Informed by QSP Modeling
ADG126 | SITC 2023

Interim Results of a Phase 1b/2 Study of ADG126 (a Masked anti-CTLA-4 SAFEbody®) Monotherapy and in Combination with Toripalimab (an anti-PD-1 Antibody) in Patients (pts) with Advanced / Metastatic Solid Tumors
ADG126-1001 | AACR 2023

Initial Results of a Phase 1b/2 Study of ADG126 (a Masked Anti-CTLA-4 SAFEbody®) in Combination with Pembrolizumab (an Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors
ADG126-P001 | AACR 2023

Results Demonstrate Highly Differentiated Safety and PK Profile of ADG126, a Masked anti-CTLA-4 SAFEbody® in Patients with Advanced Solid Tumors Phase 1
ADG126 | ESMO 2022

Phase 1 study of ADG126, a novel masked anti-CTLA-4 SAFEbody, that combines tumor-localized activation with strong Treg depletion and soft ligand blocking in patients with advanced solid tumors
ADG126 | ASCO 2022

A Novel Anti-CTLA-4 Checkpoint Inhibitor Prodrug to Address On-target Off-tumor Toxicity for Cancer Immunotherapy
ADG126 | AACR 2021

ADG116

A Phase 1b/2 Study of a Novel Anti-CTLA-4 NEObody™ ADG116 Monotherapy and in Combination with Toripalimab (TORI; Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors
ADG116 | SITC 2022

A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of an Anti-CTLA-4 NEObody™ ADG116 in Combination with Pembrolizumab (Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors: A Preliminary Update
ADG116 | SITC 2022

Phase 1 dose-finding study of a novel anti–CTLA-4 antibody ADG116 as monotherapy in patients with advanced solid tumors
ADG116 | ESMO IO 2021

Development of a novel antagonist anti-CTLA-4 antibody for cancer immunotherapy
ADG116 | SITC 2019

ADG106

Assessment of Biomarker Kinetics for ADG106 (anti-CD137 Agonist) as Monotherapy or Combined with Toripalimab
ADG106 | ESMO IO 2021

Identification of a predictive biomarker and two pharmacodynamic biomarkers to ADG106 treatment, a novel anti-CD137 agonist antibody, in phase I clinical trials
ADG106 | ASCO 2021

Phase 1, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced solid tumors or relapsed/refractory non-Hodgkin lymphoma
ADG106 | ASCO 2020

A Safe and Potent Agonist ADG106 Targeting a Unique Epitope of CD137 with Novel Mechanism of Actions
ADG106 | EORTC-NCI-AACR 2019

ADG206

ADG206, an anti-CD137 agonistic POWERbody^TM with tailor-made efficacy and safety profiles by strong crosslinking and tumor selective activation for single agent and combinational cancer immunotherapy
ADG206 | AACR 2022

Preclinical Candidates

ADG153

ADG153, a novel masked anti-CD47 IgG1 SAFEbody, demonstrates strong in vivo anti-tumor activities in preclinical solid tumor models and preferential CD47 target engagement in the tumor microenvironment
ADG153 | AACR 2023

ADG153-G1, a highly differentiated anti-CD47 IgG1 SAFEbody, demonstrates potent in vivo anti-tumor activities with enhanced ADCC/ADCP effects and significantly reduced RBCrelated and antigen sink liabilities
ADG153 | AACR 2022

ADG153, an Anti-CD47 Monoclonal Antibody Prodrug, Has Strong In Vivo Anti-Tumor Activity, Minimal RBC-Related and Antigen Sink Liabilities, and Extended Half Life in Comparison with Benchmark Clinical Antibodies of the Same IgG Subclass
ADG153 | ASH 2021

ADG138

ADG138, A Novel HER2xCD3 POWERbody^TM Integrating Bispecific TCE with Precision Masking to Control Cytokine Release Syndrome and On-Target Off-Tumor Toxicity for Single Agent and Combination Therapies in HER2-Expressing Solid Tumors
ADG138 | AACR 2022

ADG152

ADG152, a Novel CD20xCD3 T Cell Engager Prodrug with Enhanced Therapeutic Index, Demonstrates Strong Anti-Tumor Activity with Improved Safety
ADG152 | ASH 2021

Tumor-targeted CD28 bispecific POWERbody

Tumor-targeted CD28 bispecific POWERbody^TM for safe and synergistic T cell-mediated immunotherapy
CD28 bispecific POWERbody | AACR 2022